Proteins, the molecular machines that carry out the majority of the functions within a cell, are typically seen as possessing a specific three-dimensional structure. Cellular processes (e.g. reproduction) are activated or deactivated by a molecular choreography that involves the binding of one protein to another. Of late, it has been recognized that even a small protein (say, of size 50 residues) can binding to multiple partners – this results in an advantageous situation for the cell wherein depending on the identity of the partner a different functional response can be generated. In parallel, it has become increasingly evident that a single static structure is a poor representation...
In “L’Observatori”, broadcasted by Radio4, IRB Barcelona researcher Modesto Orozco explains his research efforts devoted to the development of new drugs that improve the people’s quality of life. The agreements drawn up by his laboratory with various I+D programmes from the private sector are good examples of these efforts.
Several national media, such as La Vanguardia and RTVE, echoed the publication of the genome sequence of chronic lymphocytic leukemia in last Sunday’s advanced online version of Nature. The study, which involves Modesto Orozco and Josep L. Gelpí, both with the Joint Programme on Computational Biology between IRB Barcelona and the Barcelona Supercomputing Center (BSC), does not end here. Cells of 500 patients will be analyzed, with the hope of identifying alterations in cellular mechanisms that might serve as therapeutic targets in this disease.
Using state-of-the-art technology, they seek to unraveled the genome of patients with chronic lymphocytic leukemia and give new key insights into the disease.
The study, which is a scientific milestone in this country, identifies four genes whose mutation causes this kind of leukemia.
Read the news
Read the news
The agreements drawn up by IRB Barcelona with various I+D programmes aim to strengthen technology transfer in order to benefit society.
IRB Barcelona and the BSC show their commitment to computational biology by renewing the Joint IRB-BSC Programme, which also doubles in the number of researchers involved.
The programme aims to position itself as an international leader in computational biology.
The new data base, which includes 1,700 proteins in motion, allows a more efficient design of drugs.
MoDEL holds 30% of human therapeutic targets and the objective is to cover 80% in three years.
The prediction of the structure and function of biological macromolecules (i.e., the machinery of life) is of foremost importance in the field of structural biology.